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Abstract
Down syndrome (DS) is caused by the presence of part or an entire extra copy of chromosome 21, a phenomenon that can cause a wide 
spectrum of clinically defined phenotypes of the disease. Most of the clinical signs of DS are typical of the aging process including dysregulation 
of immune system. Beyond the causative genetic defect, DS persons display epigenetic alterations, particularly aberrant DNA methylation 
patterns that can contribute to the heterogeneity of the disease. In the present work, we investigated the levels of 5-hydroxymethylcytosine 
and of the Ten-eleven translocation dioxygenase enzymes, which are involved in DNA demethylation processes and are often deregulated 
in pathological conditions as well as in aging. Analyses were carried out on peripheral blood mononuclear cells of DS volunteers enrolled 
in the context of the MARK-AGE study, a large-scale cross-sectional population study with subjects representing the general population 
in eight European countries. We observed a decrease in 5-hydroxymethylcytosine, TET1, and other components of the DNA methylation/
demethylation machinery in DS subjects, indicating that aberrant DNA methylation patterns in DS, which may have consequences on the 
transcriptional status of immune cells, may be due to a global disturbance of methylation control in DS.
Keywords: 5-hydroxymethylcytosine, TET enzymes, DNA methylation, aging
Down Syndrome (DS) is the most common genetic autosomal dis-
order compatible with life in humans. In the majority of cases, DS 
is a whole-chromosome trisomy due to meiotic nondisjunction 
of chromosome 21. The phenotypical features of the disease are 
multiple and heterogeneous, and they mainly comprise intellectual 
disability, growth defects, and endocrine disorders. Moreover, DS 
individuals are characterized by an acceleration of the aging pro-
cess, affecting particularly the immune and central nervous system. 
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In fact, individuals with DS show alterations of innate and adap-
tive immunity cell subsets and are more prone to develop dementia 
and Alzheimer’s disease (1–3). Accordingly, we recently demon-
strated that neuropsychological functions and adaptive skills show 
an age-associated decline in persons affected by DS, including those 
recruited in the MARK-AGE study and further studied in this work 
(4,5). Moreover, an accelerated aging was also revealed in DS when 
N-glycans were analyzed (6).
Recently, much effort has been invested into the investigation of 
epigenetic signatures in DS persons (7,8). Attention has mainly been 
focused on DNA methylation for its prominent role in the control of 
gene expression both in physiological and pathological conditions. In 
mammals, DNA methylation originates from the addition of a methyl 
group to cytosine bases, generally located at the CpG dinucleotides, 
by the DNA methyltransferase (DNMT) family enzymes (DNMT1, 
DNMT3A, and DNMT3B) to form 5-methylcytosine (5mC). DNA 
methylation patterns are established and maintained to define tran-
scriptional networks associated with cell-type identity. Several proteins 
are involved in the regulation DNA methylation dynamics including 
chromatin readers of 5mC, methylation-sensitive transcription fac-
tors, and, particularly, the Ten-eleven translocation (TET) family of 
DNA hydroxylases. In fact, TET enzymes (TET1, TET2 and TET3) 
catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), 
5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which can act 
as distinct epigenetic marks or represent intermediates of DNA dem-
ethylation. In particular, TET-mediated active DNA demethylation 
entails the thymine DNA glycosylase (TDG)-mediated DNA repair 
pathway for the removal of unnecessary oxidized 5mC (9).
A number of epigenome-wide analyses have shown differences in 
DNA methylation patterns between DS and control persons in brain, 
blood, buccal epithelial cells, and extra-embryonic tissues (8,10,11). 
These studies unambiguously demonstrated that in DS aberrantly 
methylated regions are distributed across all chromosomes and not 
limited to chromosome 21. Both hypermethylation and hypometh-
ylation events were found in DS samples, although the incidence of 
hypermethylation was generally higher in brain regions and placenta 
(8,10,11). The accelerated aging phenotype of DS is mirrored by epi-
genetic alterations, as the disease increases DNA methylation age 
in whole blood (on average, 4.6 years), in leukocytes (on average, 
3.9  years), and in brain (on average, 11.5  years) (12). Moreover, 
DNA methylation changes were already detectable in fetal and early 
postnatal development (8).
The contribution of 5hmC in DS pathology, however, is less char-
acterized. Down-regulation of TET genes was suggested to be asso-
ciated with DNA hypermethylation in placenta from DS samples 
(11), whereas hypomethylation of a TET1 gene regulative region (ie 
TET1 CpG island 3′-shore) was demonstrated to occur in whole 
blood from DS persons compared with their siblings (10). Only 
recently, a report has highlighted that 5mC and 5hmC additively 
account for most of the alterations of DNA methylation in DS cere-
bellum. A part of these alterations, however, were at the expense of 
5hmC only; in that case, the levels of 5hmC were mainly decreased 
in DS samples (8). Notably, global changes in 5hmC levels have been 
identified in several neurodegenerative conditions (eg Alzheimer’s 
disease and multiple sclerosis), and loss of 5hmC is considered a 
hallmark of cancer. Moreover, we and others have recently demon-
strated that blood cells undergo a gradual loss of 5hmC in aging 
(13,14). In particular, we demonstrated that the reduction of 5hmC 
was accompanied by decreased expression of TET1 and TET3 (14). 
Our results were obtained on peripheral blood mononuclear cells 
(PBMCs) deriving from volunteers enrolled in the Europe-wide 
cross-sectional population study “MARK-AGE.” In this context, 
also a cohort of DS persons was recruited because DS shares simi-
larities with progeroid diseases, due to the precocious occurrence 
of age-associated features (1,3). In order to assess the role of DNA 
hydroxymethylation in DS immune cells we analyzed 5hmC levels 
and the expression of TET genes in PBMCs from DS persons com-
pared with control individuals.
Materials and Methods
Study Population, Recruitment, Data, and Blood 
Collection
PBMC samples used in the present work derived from an Italian co-
hort of DS blood donors (n = 50; age mean = 40 ± 12; 48% female) 
and control volunteers from Italy (n = 45; age mean = 49 ± 12; 43% 
female) that have been recruited in the context of the MARK-AGE 
project (5,15,16). A group of young (n = 52; age mean = 38 ± 4; 
58% female) individuals and another one of elders (n  =  49; age 
mean  =  78  ±  2; 45% female), enrolled in the same project from 
different European countries and previously tested (14), were also 
used for comparison with DS samples. The recruitment procedure 
and PBMC isolation details have been published (17,18). Briefly, 
PBMCs were isolated from EDTA-whole blood, obtained by phle-
botomy after an overnight fasting, by discontinuous density gra-
dient centrifugation in Percoll. Isolated cells were subsequently 
cryopreserved, stored in liquid nitrogen, and shipped to the MARK-
AGE Biobank located at the University of Hohenheim, Stuttgart, 
Germany. From the Biobank, coded samples were subsequently sent 
to the Sapienza University of Rome on dry ice, where they were 
stored in liquid nitrogen.
RNA Extraction and cDNA Synthesis
Samples were thawed by incubation at 37°C, followed by dropwise 
addition of RPMI containing 10% FCS to a final dilution of 1:20. 
After centrifugation, cells were processed for RNA extraction by 
using RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions and subjected to DNase I  digestion using RNase-free 
DNase (Qiagen). RNA concentration, purity, and integrity were 
evaluated as previously described (19). Reverse transcription was 
carried out using the SuperScript VILO cDNA Synthesis Kit (Life 
technologies) on equal amounts of total RNA.
Real-Time Quantitative RT-PCR
The expression of candidate genes was determined by quantitative 
PCR using Taqman Gene Expression Assays (Applied Biosystems) 
following the manufacturer’s protocol on the iCycler IQ detec-
tion system (Bio-Rad). Each set of primers and probe showed an 
efficiency of 90%–100%. Assays were performed in duplicate 
with 30 ng of reverse transcribed RNA. Gene expression analysis 
was performed by the relative calibrator normalized quantifica-
tion method using the expression level of the β-glucuronidase gene 
(GUSB) as reference (19). An inter-run calibration sample was used 
in each plate to correct for technical variance between runs and to 
compare results from different plates. The calibrator consisted of 
cDNA prepared from HEK293T cells. Taqman Gene Expression 
Assays IDs for each set of primers and probe were as follows: 
Hs00286756_m1 (TET1); Hs00758658_m1 (TET2); Hs00379125_
m1 (TET3); Hs00702322_s1 (TDG); Hs00154749_m1 (DNMT1); 
Hs01027166_m1 (DNMT3A); Hs00171876_m1 (DNMT3B); and 
Hs99999908_m1 (GUSB).
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Dot Blot Assay
DNA was extracted from PBMCs with DNeasy Blood & Tissue 
Kit (QIAGEN), denatured in 0.4 M NaOH, 10  mM EDTA at 
95°C for 10 minutes, and then neutralized by adding an equal 
volume of ice-cold 4 M ammonium acetate (pH 7.0). Two-fold 
dilutions of DNA samples (250  ng) were spotted on the posi-
tively charged nylon membranes Hybond-N+ (Amersham 
Biosciences) in an assembled Bio-Dot apparatus (Bio-Rad). After 
vacuum-mediated blotting, the membrane was washed with 2× 
SSC buffer, air-dried, and blocked with 5% nonfat dry milk fol-
lowed by incubation with primary polyclonal anti-5hmC anti-
body (Active Motif). After incubation with HRP-conjugated 
secondary antibody, signals were visualized by chemilumines-
cence (Amersham ECL Western Blotting detection reagents). To 
correct for technical variance between replicates and to compare 
results from different experiments, control DNA obtained from 
HEK293T cells was used in all assays. Filters were stained with 
0.02% methylene blue (MB) in 0.3 M sodium acetate (pH 5.2) 
to monitor DNA loading. Densitometric analysis was performed 
by Quantity One Software (Bio-Rad Laboratories) according to 
manufacturer’s instructions.
EpiTYPER Assay for Quantitative DNA Methylation 
Analysis
The EpiTYPER assay (Sequenom) was used to quantitatively assess 
the DNA methylation state of TET1 CpG island. DNA (1  μg) 
was bisulfite-converted using the EZ-96 DNA Methylation Kit 
(Zymo Research) with the following modifications: incubation 
in CT buffer for 21 cycles of 15 minutes at 55°C and 30 seconds 
at 95°C, elution of bisulfite-treated DNA in 100 μl of water. PCR 
was performed on 10  ng of converted DNA using TET1 CGI_
Fw: aggaagagagGGTTTTTAGTTTTAA GTTTGTATTAGTTTT 
and TET1 CGI_Rev: cagtaatacgactcactataGGGAGAAGGC 
TATCATACAACCCTACCTACCTCTCC primers.
Statistical Analysis
For continuous variables, normal distribution of data was veri-
fied by Kolmogorov–Smirnov and Shapiro–Wilk normality tests 
(data not shown). Log transformation of data was used, as some 
variables were not normally distributed. When log-transformed 
data displayed normal distribution parametric tests were applied, 
otherwise, we used nonparametric tests. In particular, the identi-
fication of potential critical variables that can affect the variable 
under examination was performed by Mann–Whitney U-test and 
Student’s t-test for two-group comparisons. One-way ANOVA fol-
lowed by Tukey’s post hoc test was used for more than two inde-
pendent groups. When a significant p-value was found, a multiple 
comparison test by generalized linear models (GLMs) was per-
formed and pairwise comparisons (adjusted for multiple compari-
sons by Dunn’s and Bonferroni’s methods for the Kruskal–Wallis 
and the GLM tests, respectively) were used to identify significant 
differences between percentile groups of each categorized variable. 
The Bonferroni adjustment for multiple comparisons was used to 
confirm differences between subgroups. GLMs were also used to 
investigate the influence of confounding variables (tested as cat-
egorized and continuous variables) on group-related changes of 
analyzed parameters. Pearson correlations were used to assess 
associations between defined variables. All statistical analyses 
were carried out using SPSS software (SPSS Inc., Chicago, IL; 
Version 22.0).
Results
Analysis of 5hmC Levels in PBMCs From DS 
Samples
The content of 5hmC was measured by dot-bot assay on DNA from 
PBMCs obtained from DS persons and healthy controls. As shown 
in Figure 1, the levels of 5hmC are lower in DS samples compared 
with controls, as determined by Mann–Whitney U-test (p = .0037). 
To determine the influence of the covariates gender, age, and leuko-
cyte composition (lymphocyte/monocyte ratio) on the 5hmC levels, 
Figure  1. 5-hydroxymethylcytosine levels are decreased in DS PBMCs. (A) 
Scatter plot showing median and interquartile ranges of 5hmC levels in 
DS and control (C) subjects. Statistical analysis was performed by Mann–
Whitney U-test. (B) Representative dot blot of DNA from DS and control 
subjects performed by using anti-5hmC antibody (left panel) and methylene 
blue (MB) staining (right panel) as a DNA loading control, **p < .01.
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the multivariate tests and the GLM procedures were computed 
(Supplementary Tables 1 and 2). These analyses demonstrated that 
the difference in 5hmC content between DS and controls was inde-
pendent of any of those variables.
Expression of TET Genes in PBMCs From DS 
Samples
Subsequently, analyses were performed to see if the reduction of 
5hmC levels in DS samples was associated with a deregulation of 
the enzymes involved in 5hmC formation. Expression of the 5mC-
hydroxylase enzymes TET1, TET2, and TET3 was assessed by the 
real-time PCR analyses demonstrating that the levels of TET1 and 
TET2 were reduced in DS samples with respect to controls (TET1 
t-test: p < .001; TET2 Mann–Whitney U-test: p = .0295; Figure 2). 
However, multivariate test analysis demonstrated that the expres-
sion of TET2 was affected by confounding factors while TET1 ex-
pression was independent of age, gender and lymphocyte/monocyte 
ratio, as also highlighted by GLM analysis (Supplementary Tables 1 
and 3). The significant decrease in TET1 expression in DS sample 
was also confirmed by a generalized mixed linear model introducing 
batch effects as random factor (Supplementary Table 4). As concerns 
TET3, its expression was slightly reduced in DS samples, but this re-
sult was not statistically significant (TET3 t-test: p = .0926; Figure 2) 
and affected by covariates (Supplementary Table 5).
We then analyzed the correlation between 5hmC levels and ex-
pression of TET genes demonstrating a positive association with 
TET1 (r = 0.2729, p = .0131) and also a positive trend, albeit not sig-
nificant, with TET2 (r = 0.1959, p = .0778; Supplementary Figure 1). 
A possible coregulation between TET enzymes was also tested by 
correlation analysis and a relevant association of TET2 with TET3 
was observed (r = 0.3595, p = .0003), but not of TET1 with both of 
them (r(TET2) = 0.131, p = .2081; r(TET3)= −0.0413, p = .6711).
DNA Methylation Analysis of TET1 CpG Island
To investigate whether DNA methylation is responsible of TET1 
down-regulation in PBMCs from DS persons, quantitative analysis 
of DNA methylation and identification of differentially methylated 
CpG sites at the CpG island of TET1 gene were assessed by using 
MassARRAY EpiTYPER. The analysis was performed with primers 
encompassing a 215-bp DNA region mapped to chr10:70,320,251-
70,320,466. The comparison of the epigenetic profile between DS 
and control healthy individuals demonstrated that few CpGs present 
at the TET1 CpG island were slightly but significantly hypermethyl-
ated in DS PBMC samples (Figure 3 and Supplementary Figure 2A). 
As some of those CpGs were also shown to undergo hypermethyla-
tion with aging, we compared the DNA methylation levels at TET1 
CpG island in DS with a group of elderly population (age range: 
69–74 years), and in this case, no difference was observed at any 
CpG (Supplementary Figure 2B).
Expression of DNMTs and TDG in PBMCs From DS 
Samples
To better characterize changes in relevant epigenetic enzymes con-
nected with 5hmC in DS samples, the expression of the active DNA 
methyltransferase enzymes (DNMT1, DNMT3A, and DNMT3B) 
and of TDG, the main glycosylase involved in TET-mediated 
DNA demethylation, was also assessed. Results demonstrated 
that the levels of DNMT1 and DNMT3B mRNA were similar be-
tween DS and control samples (DNMT1 Mann–Whitney U-test: 
p =  .4808; DNMT3B Mann–Whitney U-test: p =  .2829), whereas 
DNMT3A and TDG genes were down-regulated in PBMCs from 
DS persons (DNMT3A Mann–Whitney U-test: p < .0001; TDG 
t-test: p  =  .0136; Figure  4). These differences were confirmed by 
multivariate tests and GLM analysis (Supplementary Tables 1, 6, 
and 7), which also highlighted that the expression of DNMT3A 
Figure  2. TET1 expression levels are decreased in DS PBMCs. Scatter dot 
plot showing median and interquartile ranges of TET1 (A), TET2 (B), and 
TET3 (C) mRNA levels in DS and control (C) subjects. Statistical analysis was 
performed by unpaired t-test for TET1 and Mann–Whitney U-test for TET2, 
*p < .05; ***p < .001.
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was partially influenced by the leukocyte composition of PBMCs 
(Supplementary Table  6). In particular, the impact of lymphocyte/
monocyte ratio on DNMT3A expression was mainly ascribable to 
control individuals, as a relevant positive correlation was observed 
in them (r = 0.4710, p = .0033) but not in DS persons (r = −0.01432, 
p = .9222; Supplementary Figure 3). In addition, due to the clear-cut 
Figure 3. DNA methylation levels at the TET1 CpG island in DS and control 
PBMCs. Graphs represent the CpGs at TET1 CpG island showing difference 
in DNA methylation between DS and control (C) subjects. DNA methylation 
analysis was performed by epiTYPER assay. Statistical significance was 
determined by unpaired t-test, *p < .05; ***p < .001.
Figure 4. The expression levels of DNMT3A and TDG are decreased in DS 
PBMCs. Scatter plot showing median and interquartile ranges of DNMT1 (A), 
DNMT3A (B), DNMT3B (C), and TDG (D) levels in DS and control (C) subjects. 
Statistical analysis was performed by Mann–Whitney U-test for DNMT3A and 
unpaired t-test for TDG, *p < .05; ***p < .001.
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reduction of DNMT3A in DS, we tested a possible association with 
the levels of 5hmC and TET genes demonstrating a positive cor-
relation with TET2 (r  = 0.2302, p  =  .03) and TET3 (r  = 0.3895, 
p = .0002) but not with TET1 (r = 0.1259, p = .2396) and 5hmC 
(r = 0.07261, p = .5275; Supplementary Figure 4).
Analysis of 5hmC and DNA Methylation/
Demethylation Machinery in DS, Young Persons, 
and Elders
As DS is considered a disease with premature aging features, we 
decided to compare the variables so far analyzed in DS with groups 
of young (age range: 31–45  years) and elderly people (age range: 
69–74  years) previously assessed (14). Notably, we observed that 
levels of 5hmC, TET1, and TET3 in DS were significantly lower than 
young persons but not different from the elderly group (Figure 5), 
also when considering gender, country of origin and leukocyte com-
position as covariates in GLM analysis (Supplementary Tables 8–10). 
On the contrary, DNMT1 expression was lower in the elderly popu-
lation than both DS and young persons (Supplementary Figure 5), 
but GLM analysis did not confirm the result due to a relevant influ-
ence of recruitment center (Supplementary Table 11). A difference 
between groups was obtained for TDG by GLM analysis independ-
ently of covariates but the pairwise comparison was statistically 
significant only for young and old people groups (Supplementary 
Figure 5 and Supplementary Table 12). No change was observed for 
TET2 and DNMT3B expression (Figure 5, Supplementary Figure 5, 
and Supplementary Tables 13 and 14), whereas DNMT3A was not 
tested as no data were available for the young and old populations. 
Moreover, it is noteworthy that most of variables (ie 5hmC, TET1, 
TET3, TDG, and DNMT1) showed a negative correlation with age 
when considering young and old people together, but this associ-
ation was lost when DS persons were included. Only the negative 
correlation of DNMT1 with aging was retained when all samples 
were grouped (Supplementary Table 15).
Discussion
The presence of an extra-copy of genes located in chromosome 21 
has long been considered the only driving cause for the DS pathogen-
esis. However, DS does not only originate from aneuploidy of the en-
tire or fragmented chromosome 21 itself, but different DNA regions 
have been identified to be affected by trisomy and associated with 
different phenotypes. Along with the gene dosage theory, studies on 
both murine and human models have suggested that several other 
mechanisms determine the DS phenotype. In fact, the complexity of 
DS also depends on the trans effects that each karyotype can induce 
on distal genomic loci by physical interactions due to higher-order 
structure of chromatin. Moreover, much importance has been attrib-
uted to epigenetics in the pathogenesis of DS as numerous papers 
have highlighted trans effects of trisomy 21 also on DNA methy-
lation patterns (7,8). Regions that are differentially methylated in 
healthy and DS individuals are largely distributed along the entire 
genome in several tissues. Most of the DNA methylation differences 
are tissue specific, but a certain degree of overlap has been shown in 
brain and T-cells and largely corresponding to specific transcription 
factor binding sites (8).
The contribution of 5hmC in DS was investigated in brain (8), 
the tissue with the highest levels of DNA hydroxymethylation, in 
which differentially hydroxymethylated regions were observed in 
genes largely related to brain development and function. In addition, 
Figure 5. 5hmC levels as well as TET1 and TET3 expression were similar 
between DS samples and an elderly population. Scatter plot showing 
median and interquartile ranges of 5hmC (A), TET1 (B), TET2 (C), and 
TET3 (D) levels in DS persons, young (Y) persons (age: 31–45 years) and 
old (O) persons (age: 69–74  years). Statistical analysis was performed 
by one-way ANOVA with post hoc Tukey’s test, *p < .05; **p < .01; ***p 
< .001.
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hyperhydroxymethylation has been shown to characterize the in-
ternal promoter region of the PR domain containing 8 (PRDM8) 
gene in PBMCs of DS samples, in which an up-regulation of the 
associated transcript variant 2 was observed (20).
Our present work is the first one describing alterations of 5hmC 
in blood cells from DS persons. In particular, we provide evidence of 
decreased 5hmC levels in DS, an event frequently occurring in many 
multifactorial pathological conditions, such as cancer and neurode-
generation (21,22). Notably, 5hmC reduction has also been observed 
in another chromosomal disorder known as constitutional trisomy 8 
mosaicism (23). The drop of 5hmC in DS samples is mainly associ-
ated with the down-regulation of TET1. Moreover, we show hyper-
methylation of few CpGs at TET1 promoter in DS samples when 
compared with age-matched controls, but this slight increase in 5mC 
is unlikely to explain by itself the silencing of TET1. Notably, we 
observed no difference with the methylation profile of a group of 
elderly population enrolled in the context of the same project (14). 
This result together with the evidence that 5hmC, TET1, and TET3 
in DS show similar level of the elderly population and lower than 
the young one supports the view of DS as a disorder characterized 
by premature aging features.
Alteration of DNA methylation is by now a well-established phe-
nomenon occurring in DS (8,24), but, at least in blood, no informa-
tion exists about the levels of DNMT enzymes. Our analysis of the 
transcripts of the active methyltransferases demonstrated a down-
regulation of DNMT3A in DS PBMCs. A  reduction of DNMT3A 
expression along with DNMT3B has been recently reported in DS 
brain (25), whereas no difference for DNMT3A was observed in 
induced pluripotent stem cells generated from the twins discordant 
for DS (26). In addition, deregulation of DNMT3A as well as of other 
DNMTs has been documented in several tissues during aging (27–29).
Among the clinical manifestations typical of both aging and DS, 
5hmC and TET deregulation in PBMCs may contribute to the de-
cline of immune function, which is associated with increased suscep-
tibility to infection and autoimmune diseases. New-borns with DS 
already show an abnormal structure of thymus, the central organ of 
T lymphocytes differentiation, with a concomitantly decreased pro-
duction of mature T cells in the periphery (30). Notably, dynamic 
changes of 5hmC have been characterized during development and 
differentiation of T-cell lineage. Thymus-specific enhancers and gene 
bodies of highly transcribed genes showed enrichment of 5hmC. 
Moreover, higher levels of 5hmC were detected in active genes of 
precursor cells, suggesting the functional importance of 5hmC in 
T-cell specification (31). 5hmC-driven active demethylation has also 
been implicated in the thymic development of regulatory T cells 
(Tregs), a small subpopulation of T cells with fundamental roles in 
immune homeostasis control and thus in the suppression of auto-
immunity. In fact, TET1 and TET2 activities were demonstrated to 
mediate the demethylation-dependent activation of FOXP3 gene, 
the master regulator of Tregs development and function (32,33). In 
addition, DS persons also have a significantly higher risk of develop-
ing leukemia, particularly acute lymphoblastic leukemia and acute 
megakaryoblastic leukemia (34), the onset of which has been shown 
to be accompanied by sequential epigenetic changes in DS (35). 
Notably, loss of 5hmC is a typical feature of blood cell malignan-
cies and of solid tumors as well (36). TET1 expression is frequently 
deregulated in solid tumors, but a prominent role in the regulation 
of B-cell malignancies has been demonstrated, and evidence of its 
mutations exists in T-acute lymphoblastic leukemia (37–39). TET2 
is a master regulator of normal hematopoiesis, and mutations of 
the TET2 gene have been frequently identified in multiple spectra 
of myeloid malignancies (40,41). Similarly, among DNMT enzymes, 
DNMT3A represents one of the most frequently mutated genes 
in diverse types of hematological cancers (41). Finally, it is worth 
noting that DNMT3A and TET2 mutations are also frequently 
observed in age-related clonal hematopoiesis (42), suggesting a cen-
tral role of these two enzymes in age-related phenotypes and tumor 
development.
In conclusion, our analysis of DNA hydroxymethylation in 
PBMCs from DS patients demonstrated a decrease in 5hmC levels 
and components of the relative enzymatic machinery. The positive 
correlation between TET1 expression and 5hmC levels may suggest 
a causative role of TET1 down-regulation in DNA hypermethyla-
tion in DS patients. Viewed together, our results further strengthen 
the evidence that multiple pathological states are associated with 
deregulation of 5hmC that can contribute to the establishment of 
disease-associated DNA methylation patterns. Apart from being 
an intermediate in DNA demethylation processes, 5hmC directly 
controls gene expression programs acting as an epigenetic mark in 
its own right, recognized by specific chromatin readers. Therefore, 
the epigenetic consequences downstream of 5hmC alteration in blood 
cells can induce age-related clinical impairment of DS immune system 
(eg immunosenescence), with higher occurrence of infections, hema-
tological malignancies, and autoimmune diseases in DS persons.
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